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No evidence for a specific role of 1gM in mesangial proliferation of
idiopathic nephrotic syndrome. To define the relationship of mesangial
1gM to various morphologic categories of idiopathic nephrotic syn-
drome (INS), an analysis of 100 patients was carried out in which five
morphologic subgroups were evaluated: group 1, minimal glomerular
change (38 patients); group 2, minimal change with focal global sclerosis
(18 patients); group 3, focal segmental glomenilosclerosis (FSG) (23
patients); group 4, mesangial proliferation (12 patients); group 5, focal
segmental glomerulosclerosis with mesangial proliferation (9 patients).
Immunohistochemical studies failed to demonstrate any differences
between these five groups. The intensities of immunofluorescence and
the percentage of tissue samples demonstrating 1gM and/or C3 in the
glomerular mesangium and subendothelial regions were similar. In
addition, the presence or intensity of mesangial 1gM did not predict the
patients' current status or responsiveness to steroid therapy. Morpho-
logic transitions were observed in patients who had more than one
biopsy: one of five in group 2 and two of eight in group 3 developed
mesangial proliferation; and nine of ten patients with mesangial prolif-
eration in the first biopsy continued to show this finding in the second.
In general, a complete response to steroid therapy and a favorable
outcome is less likely in patients with this morphologic abnormality. In
nine of the 27 repeat biopsies, there was lack of agreement between the
first and second tissue samples with respect to the presence or absence
of mesangial 1gM. Although mesangial proliferation is a consistent
feature of the morphology of certain patients with INS, these studies do
not support a unique association with mesangial 1gM.
Absence de preuve d'un role spécifique de l'IgM sur Ia proliferation
mésangiale du syndrome nephrotique idiopathique. Afin de définir Ia
relation entre 1gM mesangiale et les différentes categories morphologi-
ques de syndrome néphrotique idiopathique (INS), une analyse de 100
malades a été effectuée, avec evaluation de cinq sous-groupes morpho-
logiques: groupe I, lesions glomérulaires minimes (38 malades); groupe
2, lesions minimes avec sclérose globale focale (18 malades); groupe 3,
glomérulosclérose focale et segmentaire (FSG) (23 malades); groupe 4,
proliferation mesangiale (12 malades); groupe 5, glomérulosclerose
focale et segmentaire avec proliferation mesangiale (9 malades). Les
etudes immunohistochimiques n'ont pas permis de démontrer de differ-
ences entre ces cinq groupes: Les intensités en immunofluorescence et
Ic pourcentage des exemples tissus indiquant de l'IgM et/ou du C3 dans
le mesangium glomerulaire et les regions sous endothCliales étaient
identiques. De plus, Ia presence ou l'intensité de I'IgM mésangiale ne
prejugeait pas de l'état des malades, ni de Ia réponse au traitement
stCroidien. Des transitions morphologiques ont eté observées chez des
malades qui avaient plus d'l biopsie: un sur cinq dans Ic groupe 2 et
deux sur huit dans Ic groupe 3 ont développe une proliferation mésan-
giale; neuf de dix malades avec une proliferation mésangiale a Ia
premiere biopsie ont continue a avoir cette anomalie a La seconde. En
gCnCral, une rCponse complete au traitement stéroidien, et une évolu-
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tion favorable sont moms probables chez les malades ayant cette
anomalie morphologique. Dans neuf des 27 biopsies rCpétées, II y avait
un manque de concordance entre Ia premiere et la seconde en ce qui
concerne la presence ou l'absence d'IgM mésangiale. Bien que Ia
proliferation mesangiale soit une caractCristique morphologique habi-
tuelle chez certains malades avec INS, ces etudes ne sont pas en faveur
d'une association unique avec l'IgM mesangiale.
In recent years the various clinical-pathological states associ-
ated with the nephrotic syndrome have been categorized by
detailed morphologic studies of the kidney [1]. Within the
spectrum of idiopathic nephrotic syndrome (INS) is a disorder
characterized clinically by varying degrees of steroid respon-
siveness and a high incidence in childhood and immunohisto-
chemically by the absence of immune deposits within the
peripheral glomerular capillary wall. Commonly, there is no
abnormality (nil lesion, minimal change) of the glomerular tuft,
although with electron microscopy spreading and retraction of
foot processes are observed. A second morphologic group has
been identified by the recognition of focal segmental sclerosis
[1—3] which is often associated with resistance to steroids,
progression to renal insufficiency [4—8] and a high frequency of
recurrence after transplantation [9—11]. A third group of pa-
tients with INS have diffuse mesangial proliferation associated
with normal peripheral capillary wall by light microscopy [1].
Recently, attention has been focused on the presence of 1gM in
the mesangium of some of these patients suggesting that this
association represents a specific pathogenetic entity [12, 13].
In the present study, a clinical, morphologic, and immunohis-
tochemical analysis was carried out on 100 patients with INS.
No relationship was observed between the presence of mesan-
gial 1gM and glomerular histology. Although mesangial prolif-
eration was associated with a relatively high incidence of
steroid resistance, focal sclerosis, and progression to renal
insufficiency, there is no evidence that this process was related
to deposition of 1gM within the mesangial region.
Methods
Patients and morphologic evaluation
Patients with idiopathic nephrotic syndrome (INS) referred to
the University of Minnesota Hospitals during the period 1970 to
1980 in whom kidney tissue samples had been obtained by
biopsy were analyzed retrospectively. The current indications
for renal biopsy in a patient with nephrotic syndrome include:
age greater than 8 years, gross hematuria, manifestation of
systemic disease (arthritis, rash), reduced GFR, frequently
relapsing course in childhood that results in steroid-toxicity
justifying cytotoxic therapy, and steroid resistance. All tissue
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[glomerular basement membrane (GBM), mesangial, suben-
dothelial region, stalk, juxtaglomerular region, Bowman's cap-
sule, tubular basement membrane (TBM), and blood vessel]
and pattern (linear and granular), and intensity (graded as 0,
trace, 1+, 2+, and 3+). In this retrospective study we recut and
restained the tissue samples of 53 patients (77 biopsies) which
had been maintained at —70°C. For the remaining 47 patients,
the original immunofluorescence reports and photographs were
used; the latter tissue samples had been evaluated in the same
laboratory using the same methods and morphologic criteria.
Twenty-five normal tissue samples were also evaluated for
immunofluorescence: Twenty-two of these were obtained from
donor kidneys prior to transplantation as part of another
research protocol, and three from normal segments of kidney
were removed for surgical indication.
Clinical evaluation
o The charts of patients with INS were reviewed and the
clinical course was evaluated with respect to steroid therapy as
follows: steroid-sensitive, complete remission within 4 to 6
weeks of treatment with prednisone at 60 mg/m2/day with
remission persisting for a minimum of 4 weeks after termination
0. •a of treatment; steroid-dependent, complete remission following
steroid therapy with recurrence either after tapering the dose or
• within 4 weeks after termination of treatment; steroid-resistant,
defined as no remission after 4 to 6 weeks of daily prednisone: (60 mglm2/day) given in three divided doses followed by 4
weeks of a single dose (40 to 60 mg/rn2) given every other day.
The current status is indicated as follows: remission, complete
absence of edema and proteinuria; abnormal urinalysis, persist-
ent proteinuria and normal creatinine clearance; and renal
insufficiency, decreased creatinine clearance and/or endstage
renal failure. In our patient population we had six patients who
had at least one episode of spontaneous remission (three in
group 1, one in group 2, and two in group 3). Analysis of the
significance of differences between histologic groups with re-
spect to clinical manifestations, response to steroid therapy,
current status, and presence of linear IgA was done by x2
analysis with Yates' correction.
Results
The age (range) and mean in years for the five groups are as
follows: group 1, (1.5 to 63), 9.8; group 2(1 to 70), 13.9; group 3
(1.5 to 80), 30; group 4 (0.7 to 8), 5.5; groupS (2.7 to 59), 35.6.
The male:female ratio in groups ito 5 are 2.2:1, 2.0:1, 2.3:1,
1:1, and 0.8:1, respectively. The mean follow-up (range) in
years in group 1 was 6.4 (0.25 to 19); group 2, 5.2 (0.25 to 20);
group 3, 5.0 (0.25 to 21); group 4, 3.3 (0.4 to 7.1); and group 5,
3.0 (0.75 to 8.4).
The results of immunofluorescence microscopy of the kidney
in 100 initial biopsies are summarized in Table 1 and represent-
ed in Figure 2. There were no significant differences among the
five morphologic groups. 1gM and C3 were located mainly in
the mesangiurn in a granular pattern and along the subendothe-
hal region of the capillary lumen as well as in areas of segmental
sclerosis. IgG, fibrinogen, and IgA were present usually along
the GBM in a linear pattern with an intensity of trace to 1 +
which was not considered abnormal. Of seven total patients in
which IgA was observed in the mesangium, five were of trace
intensity and two of 1-2+ intensity.
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Fig. 1. Time of biopsy after the onset of the nephrotic syndrome. Each
point represents the time of the initial biopsy in each patient after the
onset of the nephrotic syndrome in the five morphologic groups. The
current status of each patient is indicated: 0, complete remission; A,
abnormal urinalysis; •, renal insufficiency; t, dead.
samples were prepared for light microscopic evaluation in
Zenker's fixative as previously described [14]. The morphologic
diagnosis depended on criteria established by the International
Study of Kidney Disease in Children [15]. All specimens
described as minimal change, focal glomeruloscierosis, and
mesangial proliferation were evaluated. Specifically excluded
from this analysis were patients with histologic evidence of
membranous nephropathy, membranoprohiferative glomerulo-
nephritis, and other immune-mediated or defined renal lesions.
On the basis of morphology observed by light microscopy of
the first biopsy, the 100 patients were divided into five groups:
group 1, minimal glomerular change (38 patients); group 2,
minimal change with focal global sclerosis (one or more globally
sclerosed glomeruhi) (18 patients); group 3, focal segmental
glomerulosclerosis (FSG) (23 patients); group 4, mesangial
proliferation (> three cells per mesangial zone) (12 patients);
groupS, FSG with mesangial proliferation (9 patients). The time
of biopsy after the onset of the nephrotic syndrome is indicated
in Figure 1.
Immunofluorescence microscopy
Immunofluorescence studies were carried out as previously
reported [14, 16]. Antigens were characterized with respect to
distribution (diffuse, focal, and segmental), localization
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Fig. 2. Similar mesangial-subendothelial
staining for 1gM in selected tissue samples:
A normal kidney, B minimal lesion, C non-
sclerotic glomerulus in a patient with focal
segmental sclerosis with mesangial
proliferation, U mesangial proliferation,
E non-sclerotic glomerulus in a patient with
focal global sclerosis, and F non-sclerotic
glomerulus in a patient with focal segmental
sclerosis. (x 300) Compare with Figure 3.
Table 1. Immunofluorescence microscopy of the kidney in patients with the nephrotic syndrome and normal control subjects
Number and percent of patients demonstrating glomerular immunofluorescence for the indicated antigena
Controls (25) Group 1 (38) Group 2 (18) Group 3 (23) Group 4 (12) Group 5 (9)
Antigen' No. % No. % No. % No. % No. % No. %
1gM
IgA
IgG
Fibrinogen
C3
21
15
20
17
21
84.0
60.0
80.0
68.0
84.0
34
9
26
15
30
89.5
23.7
68.4
39.5
78.9
15 83.3
4 22.2
12 66.7
8 44.4
16 88.9
20 85,9
6 26.1
16 69.6
11 47.9
21 91.3
9 75.0
1 8.3
7 58.3
5 41.7
10 83.4
8
3
8
3
7
88.9
33.3
88.9
33.3
77.8
a The number of patients studied in each group is indicated in parentheses.
b 1gM and C3 were present in the mesangium and subendothelial region; IgG, IgA, and fibrinogen were present primarily along the GBM in a
linear distribution; in seven instances (two in group 1, three in group 2, two in group 3) IgA was seen in the mesangium.
Linear IgA in the GBM was significantly higher; P < 0.05, than in groups 1 to 5.
Figures 3 and 4 depict the intensity and distribution (diffuse
or segmental) of 1gM and C3 in the five groups and normal
controls. Specifically excluded from this analysis is the 1gM and
C3 in areas of focal segmental sclerosis in groups 3 and 5. No
differences were apparent among the five groups. When com-
pared with normal kidney, there was considerable overlap,
although the intensity of 1gM in some nephrotic kidneys was
greater than that observed in normal tissue samples. For
example, a grade of 1 + or greater for 1gM was seen in 2 of 25
normal tissue samples compared with 13 of 38 in group 1, 7 of 18
in group 2, 12 of 23 in group 3, 3 of 12 in group 4, and 7 of 9 in
group 5. When the 86 patients having positive mesangial
immunofluorescence for 1gM were compared with the 14 pa-
tients having no detectable 1gM, no significant differences were
observed with respect to clinical manifestations, response to
steroid therapy, or current status. In addition, when patients
were compared with respect to the intensity of mesangial 1gM
(1+ vs. >1+), no differences were observed in responsive-
ness or resistance to steroid therapy (P = 0.1 — 0.25).
Twenty-seven patients had more than one kidney biopsy. The
light morphologic classification and presence or absence of 1gM
in the initial and subsequent biopsy specimens are indicated in
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Table 2. Morphologic transitions were observed in 14 of 27
patients (53.7%): Two of five initially in group 2 (global sclero-
sis) and two of eight initially in group 3 (focal sclerosis)
developed mesangial proliferation. The subsequent biopsy
specimens of all eight patients who initially showed mesangial
proliferation (group 4) continued to demonstrate the same
lesion. However, seven of this group developed focal sclerosis
in the second or third biopsy and therefore the subsequent
biopsy specimens were classified in group 5. Also two patients
in group 1 developed global sclerosis and one patient in group 5
lost the mesangial proliferation seen on the first biopsy. Gener-
ally, there was a concurrence between mesangial 1gM in initial
and subsequent biopsy specimens although in six of 27 in-
stances, including three patients with mesangial proliferation
alone, the first biopsy specimen did not predict the presence or
absence of 1gM in the second biopsy.
No differences were apparent in response to steroids or
Table 2. The morphologic group and outcome in patients with
idiopathic nephrotic syndrome who had more than one biopsy; the
presence (+) or absence (—) of 1gM in the glomerulus is indicated
Morphologic groupa and 1gM immunofluorescence
Patient no. Biopsy I Biopsy 2 Biopsy 3 Outcomeb
1
2
3
4
1 (—)
1 (+)
1 (—)
1 (—)
I (+)
I (+)
2 (+)
2 (+)
Remission
Remission
Abnormal urinalysis
Dead
5
6
7
8
9
2 (+)
2 (—)
2 (+)
2 (+)
2 (+)
2 (+)
2 (+)
2 (—)
3 (+)
4 (+) 5 (+)
Remission
Abnormal urinalysis
Renal insufficiency
Abnormal urinalysis
Renal insufficiency
10
11
12
13
14
15
16
17
3 (+)
3 (+)
3 (+)
3 (+)
3 (+)
3 (-I-)
3 (+)
3 (+)
3 (+)
3 (+)
3 (+)
3 (—)
3 (+)
3 (+)
4 (+)
S (+)
Abnormal urinalysis
Abnormal urinalysis
Abnormal urinalysis
Abnormal urinalysis
Abnormal urinalysis
Renal insufficiency
Renal insufficiency
Renal insufficiency
18
19
20
21
22
23
24
25
4 (+)
4 (+)
4 (+)
4 (+)
4 (+)
4 (+)
4 (+)
4 (—)
4 (+)
5 (—)
5 (—)
5 (+)
5 (+)
5 (+)
5 (+)
5 (+)
5 (+)
5 (+)
5 (+)
Abnormal urinalysis
Abnormal urinalysis
Abnormal urinalysis
Abnormal urinalysis
Remission
Remission
Renal insufficiency
Renal insufficiency
26
27
5 (+)
5 (+)
5 (+)
3 (+)
5 (+) Renal insufficiency
Abnormal urinalysis
Morphologic group: 1. nil lesion; 2, global sclerosis, 3, focal
segmental sclerosis; 4, mesangial proliferation, 5, focal segmental
sclerosis and mesangial proliferation.
b The range and mean followup of the patients with abnormal
urinalysis is 1.2 to 20 years (mean, 7.6 years) and for patients with renal
insufficiency the range is 2 to 10.5 years (mean, 4.3 years).
current status between patients with mesangial proliferation
(group 4) and those with mesangial proliferation and focal
sclerosis (group 5) (Figs. S and 6). In both groups approximately
one half were resistant to steroids, and the current status with
respect to remission and persistent proteinuria is similar. In
patients with focal sclerosis (group 3), 26% were steroid-
dependent or sensitive although at followup only two of 23 were
in complete remission.
In this group of 100 patients, 17 (two from group 2; ten from
group 3; two from group 4; and three from group 5) progressed
to renal failure after an average duration of nephrotic syndrome
of 3.2 years (1 month to 6.25 years). Transplantation was
carried out in 12 patients, and recurrence of the nephrotic
syndrome was observed in three, one each from groups 3, 4,
and 5. Two patients in group 1 died: one from a cardiorespira-
tory arrest after a lung biopsy for pneumocystis carinii infec-
tion, and the other of unknown cause. One elderly patient in
group 3 died of an unrelated cause.
Discussion
Immunohistochemical studies in minimal change nephrotic
syndrome have failed to demonstrate the presence of deposits
control
Fig. 3. The intensity of glomerular mesangial-subendothelial immuno-
fluorescence for 1gM in normal control subjects and patients ofthe five
morphologic groups. The distribution within the glomerulus is indicated
as diffuse (0) or segmental (•).
3+
2+ •
o
1 + 0000 0000S 0000s 0S, 000
0000 0000 0s oco o.
Tr .o 000 00
Normal 1 2 3 4
control
Fig. 4. Intensity of glomerular immunofluorescence for C3 in normal
control subjects and patients of the five morphologic groups. The
distribution within the glomerulus is indicated as diffuse (0) or segmen-
tal (s).
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Table 3. Summary of series of patients with nephrotic syndrome and mesangial proliferation
Glomerular
Author Ref. No. of
Age mean
(range) Sex Hematuria
Hyper-
tension
Steroid
respon-
Current status immuno-
fluores-
cence forRenal
(year) no. patients years MIF number number sivea Remission Proteinuria failure IgMb
R. H. R. White [23] 8 8 3/5 8 2/6 7 1 ND
(1973)
J. Giangiacomo [31] 8 7.2 5/3 7/8 8/8
(1977) (3.5 to 12.2)
H. K. Bhasin [12] 9 (1.8 to 14.5) 7/2 2 3/8 2 7 9/9
(1978)
W. M. Murphy [19] 8 (2 to 15) 6/2 2 4/8 2 0/8
(1979)
A. H. Cohen [13] 9 28 4/5 2 2 1/5 1 8 9/9
(1978) (1.5 to 59)
R. Waldherr [29] 18 12/16 14 8 5/16 5 8 5 5/11
(1978)
E. A. Brown [28] 14 26 9/5 5 4 10/12 12 2 ND
(1979) (2 to 65)
L. Migone [32] 10 7 2 3/7
(1980)
S. Larsen [30] 9 (14 to 44) 7/2 2 2/9
(1978)
Present series
(1982)
Mesangial proliferative 12 5.8
(0.7 to 15)
6/6 10 5 5/12 5 5 2 9/12
Mesangial proliferative
plus focal sclerosis 9 23.1
(2.4 to 59)
4/5 8 5 4/8 3 3 3 8/9
The denominator refers to the number treated and the numerator the number that were responsive.
b The denominator refers to the number evaluated and the numerator the number positive for 1gM.
containing Ig or complement components along the peripheral
glomerular capillary wall. However, a number of studies have
demonstrated 1gM and C3 within the glomerular mesangium
and stalk region [14, 17, 18]. In addition, 1gM and other immune
reactants have been detected in areas of segmental sclerosis.
Although the relationship of the 1gM in areas of sclerosis to that
in the mesangium of nonsclerotic glomeruli is unknown, the
former is not restricted to nephrotic syndrome since sclerotic
lesions of many diseases demonstrate the presence of 1gM and
C3 [4]. Whether this phenomenon is a consequence of glomeru-
lar capillary collapse with impaired movement of immune
reactants in the mesangium or reflects another process is
unknown.
Recently, it has been suggested that in patients with INS, the
presence of mesangial proliferation and 1gM represents a sepa-
rate pathogenetic entity [12, 13, 19]. However, the strength of
the current study is related to the homogeneity of the pathologi-
cally defined groups and the rigorous comparison of immuno-
histochemical findings and clinical course - a circumstance not
evident in other studies [12, 13, 20]. Although our studies did
not demonstrate any association between mesangial 1gM and
steroid responsiveness in any morphologic group, studies by
Allen et al [211 indicate that the presence of mesangial immune
deposits predict a higher incidence of steroid nonresponsive-
ness, although the relationship to mesangial proliferation was
not evaluated.
The specific focus of the current study was an analysis of
patients with mesangial proliferation with respect to the rela-
tionship of 1gM deposits in the mesangium and a comparison
with other morphologic subgroups of the syndrome. Of 100
patients with INS, mesangial proliferation alone was seen in 12
and in combination with focal sclerosis in nine. This frequency
100
60
100 No therapy
Steroid-resistant
. 60 Steroid-dependent
ii 20
(2) Steroid-sensitive
Fig. 5. Response to steroid therapy in patients with idiopathic nephrotic
syndrome. The percent of patients in each of the five groups having the
indicated response to steroids is shown. The number of patients is
denoted in parentheses.
2 3 4 5
20
Died
Renal failure
Abnormal urinalysis
J Remission
(0
C
0)
(0
0
C
a)0
ci)0
Fig. 6. The Current status of patients with idiopathic nephrotic syn-
drome. The percent of patients in each of the five groups with the
indicated current status is illustrated. The number of patients is denoted
in parentheses.
1 2 3 4 5
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is relatively high when compared with other series but is
consonant with the referral nature of patients seen at this and
other institutions [221. Diffuse mesangial cell proliferation with
or without an increase in mesangial matrix and normal glomeru-
lar capillary wall by light microscopy, as described by Churg,
Habib and White [1] in 1970, has been reported in a number of
series in 2 to 5%of children [23, 24]. All patients presenting in
group 4 were children (8 months to 16 years old), and five of
nine patients in group 5 were under 16 years of age. Although
this group of patients appeared to be separable from patients
with minimal change on the basis of certain parameters, includ-
ing corticosteroid responsiveness, association with focal sclero-
sis, and progression to renal failure, the presence of 1gM
deposits in the glomerulus was not different. Indeed, immuno-
histochemical analysis failed to demonstrate any specific differ-
ences, in distribution or intensity, between patients in any of
the five morphologic categories when compared with each
other, although all five groups showed more 1gM in the mesan-
gium than did normal control tissue. Excluded from this analy-
sis was the well recognized presence of 1gM in regions of
segmental glomerular sclerosis as previously reported.
The significance of mesangial 1gM in INS is unclear. Determi-
nants of mesangial sequestration of macromolecules involve a
number of variables including those related to the macromole-
cule itself (charge, size, type, and blood level); uptake by the
mononuclear phagocytic system which controls in part the
plasma level; and characteristics of the glomerular capillary
[25]. Experimental studies have demonstrated an increase in
uptake of macromolecules by the mesangium in experimentally
induced nephrotic syndrome whether induced by aminonucleo-
side of puromycin or anti-GBM antibody [25]. The mechanism
of increased uptake is not clear but may reflect increased
mesangial perfusion in nephrotic states. It is possible that the
deposition of 1gM in the mesangium in INS reflects a similar
mechanism.
The relationship of mesangial proliferation alone (group 4) to
mesangial proliferation with segmental sclerosis (group 5) is not
completely clear from the current analysis although subsequent
biopsy specimens in nine patients of the former group demon-
strated morphologic transitions in seven to group 5. These
studies suggest that the separation of patients into groups 4 and
5 simply on the basis of segmental sclerosis may be an artificial
one, In ten patients of groups 4 and 5 whose initial biopsy
specimens demonstrated mesangial proliferation, only one pa-
tient demonstrated loss of this morphologic abnormality where-
as the remaining nine on subsequent analysis continued to show
significant proliferation. Conversely, subsequent biopsy speci-
mens in 17 patients who initially did not demonstrate mesangial
proliferation showed transition to this morphologic abnormality
in only three patients. These studies suggest a high degree of
homogeneity in the population of patients with nephrotic syn-
drome who have mesangial proliferation.
The response to corticosteroid therapy and the outcome at
followup in these 100 patients is similar to prior reports.
Although the outlook in patients with focal global sclerosis has
been reported to be similar to that of patients with minimal
change [7], other studies have suggested a worse prognosis and
a clinical course similar to that seen in patients with focal
segmental sclerosis [4, 6, 26—28]. The observations of the
present study support this latter view.
Prior studies [12, 13, 19, 23, 28—32] have suggested that
patients with mesangial proliferation either respond to steroid
and cytotoxic therapy [28] are steroid resistant but gradually
lose proteinuria spontaneously [23] or have a protracted course
and poor prognosis [29] (Table 3). The outcome of our patients
was worse than that observed in patients with minimal-change
nephrotic syndrome. After a 3-year followup, two of 12 patients
with mesangial proliferation (group 4) and three of nine with
mesangial proliferation and segmental sclerosis (group 5) pro-
gressed to renal failure; after transplantation in four, two
patients have had recurrence of INS associated with segmental
sclerosis.
The studies undertaken indicate that the presence of mesan-
gial 1gM is not associated with a specific morphologic category
such as mesangial proliferation, nor is it predictive of response
to corticosteroid therapy or clinical outcome.
These findings agree with the conclusions of Vilches et al [33]
that 1gM in the mesangium of patients with 'minimal change"
nephrotic syndrome is of no prognostic value and does not
indicate a distinct clinical entity.
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